Evidence map›Paper›PMID 38907850›Full record

ArticleClinical rheumatology2024

Systematic analysis for clinical characteristics and outcomes of IgG4-related disease patients during the COVID-19 pandemic.

Tong Zhang, Huilan Liu, Mengxin Tian, Mingzhu Zhou, Hang Zhou, Xia Zhang, Tianqi Wang, Mingxin Bai, Yuetong Xu, Fan Yang and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Tong ZhangDepartment of Rheumatology and Immunology, Beijing Friendship Hospital, Capital Medical University, 95Th, Yongan Road, Beijing, 100050, China.
Huilan LiuDepartment of Rheumatology and Immunology, Beijing Friendship Hospital, Capital Medical University, 95Th, Yongan Road, Beijing, 100050, China.
Mengxin TianDepartment of Rheumatology and Immunology, Beijing Friendship Hospital, Capital Medical University, 95Th, Yongan Road, Beijing, 100050, China.
Mingzhu ZhouDepartment of Rheumatology and Immunology, Beijing Friendship Hospital, Capital Medical University, 95Th, Yongan Road, Beijing, 100050, China.
Hang ZhouDepartment of Rheumatology and Immunology, Beijing Friendship Hospital, Capital Medical University, 95Th, Yongan Road, Beijing, 100050, China.
Xia ZhangDepartment of Rheumatology and Immunology, Beijing Friendship Hospital, Capital Medical University, 95Th, Yongan Road, Beijing, 100050, China.
Tianqi WangDepartment of Rheumatology and Immunology, Beijing Friendship Hospital, Capital Medical University, 95Th, Yongan Road, Beijing, 100050, China.
Mingxin BaiDepartment of Rheumatology and Immunology, Beijing Friendship Hospital, Capital Medical University, 95Th, Yongan Road, Beijing, 100050, China.
Yuetong XuDepartment of Rheumatology and Immunology, Beijing Friendship Hospital, Capital Medical University, 95Th, Yongan Road, Beijing, 100050, China.
Fan YangDepartment of Rheumatology and Immunology, Beijing Friendship Hospital, Capital Medical University, 95Th, Yongan Road, Beijing, 100050, China.
Yunzhi ZhufengDepartment of Rheumatology and Immunology, Beijing Friendship Hospital, Capital Medical University, 95Th, Yongan Road, Beijing, 100050, China.
Qiyuan HaoDepartment of Rheumatology and Immunology, Beijing Friendship Hospital, Capital Medical University, 95Th, Yongan Road, Beijing, 100050, China.
Difei LianDepartment of Rheumatology and Immunology, Beijing Friendship Hospital, Capital Medical University, 95Th, Yongan Road, Beijing, 100050, China.
Wenhuan ZengDepartment of Rheumatology and Immunology, Beijing Friendship Hospital, Capital Medical University, 95Th, Yongan Road, Beijing, 100050, China.
Shuju SongDepartment of Rheumatology and Immunology, Beijing Friendship Hospital, Capital Medical University, 95Th, Yongan Road, Beijing, 100050, China.
Haiyu QiDepartment of Rheumatology and Immunology, Beijing Friendship Hospital, Capital Medical University, 95Th, Yongan Road, Beijing, 100050, China.
Yanying LiuDepartment of Rheumatology and Immunology, Beijing Friendship Hospital, Capital Medical University, 95Th, Yongan Road, Beijing, 100050, China. Liuyanying6850@126.com.ORCID http://orcid.org/0009-0004-6014-0635

Funding

Capital's Funds for Health Improvement and Research 2022-2-2026Tongzhou District Science and Technology Committee KJ2023CX004
6 · The paper itself

Abstract

backgroundTo systematically describe clinical characteristics and investigate factors associated with COVID-19-related infection, hospital admission, and IgG4-related disease relapse in IgG4-RD patients.

methodsPhysician-reported IgG4-RD patients were included in this retrospective study. Using multivariable logistic regression analysis to determine factors for primary outcome (COVID-19-related IgG4-RD relapse) and secondary outcome (COVID-19-related infection and hospital admission). Covariates included age, sex, body mass index, smoking status, comorbidities, IgG4-RD clinical features, and treatment strategies.

resultsAmong 649 patients, 530 had a diagnosis of COVID-19, 25 had COVID-19-related hospital admission, and 69 had COVID-19-related IgG4-RD relapse. Independent factors associated with COVID-19 infection were age (OR, 0.98; 95% CI, 0.96-1.00), body mass index (1.10, 1.03-1.18), and tofacitinib (0.34, 0.14-0.79). Further analysis indicated that age (1.10, 1.03-1.16), coronary heart disease (24.38, 3.33-178.33), COVID-19-related dyspnea (7.11, 1.85-27.34), pulmonary infection (73.63, 16.22-4615.34), and methotrexate (17.15, 1.93-157.79) were associated with a higher risk of COVID-19-related hospital admission. Importantly, age (0.93, 0.89-0.98), male sex (0.16, 0.03-0.80), ever/current smoking (19.23, 3.78-97.80), COVID-19-related headache (2.98, 1.09-8.17) and psychiatric symptoms (3.12, 1.07-9.10), disease activity before COVID-19 (1.89, 1.02-3.51), number of involved organs (1.38, 1.08-1.76), glucocorticoid dosage (1.08, 1.03-1.13), and methotrexate (5.56, 1.40-22.08) were strong factors for COVID-19-related IgG4-RD relapse.

conclusionsOur data add to evidence that smoking and disease-specific factors (disease activity, number of involved organs, and specific medications) were risk factors of COVID-19-related IgG4-RD relapse. The results highlight the importance of adequate disease control with b/tsDMARDs, preferably without using methotrexate and increasing glucocorticoid dosages in the COVID-19 era. Key Points • COVID-19-related infection or hospital admission were associated with known general factors (age, body mass index, specific comorbidities and methotrexate) among IgG4-RD patients. • Smoking and disease-specific factors (disease activity, number of involved organs and specific medications) were associated with higher odds of COVID-19-related IgG4-RD relapse. • The results highlight the importance of adequate disease control with b/tsDMARDs, preferably without using methotrexate or increasing glucocorticoid dosages.

Indexed as

COVID-19HospitalizationImmunoglobulin G4-Related DiseaseAdultAgedAge FactorsComorbidityFemaleHumansMaleMiddle AgedRecurrenceRetrospective StudiesRisk FactorsSARS-CoV-2COVID-19IgG4-related diseaseRelapseRisk factors

Identifiers

PMID38907850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.